

Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK MIA(IMP) 40211 Insp IMP 40211/37423042-0004[I]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with :

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

The competent authority of United Kingdom confirms the following :

The Manufacturer : SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED

Site address : SYMBIOSIS PHARMACEUTICAL SERVICES LIMITED, THE BRUCE BUILDING, CASTLE BUSINESS PARK, STIRLING, FK9 4TS, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA(IMP) 40211 in accordance with Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 04/02/2025 , it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Investigational Medicinal Products

1. MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

[1.1.1.4] Small volume liquids

cytotoxics

[1.1.1.6] Other aseptically prepared products

Suspensions

Cytotoxics

[1.1.3] Batch certification

[1.2] Non-sterile investigational medicinal products

[1.2.2] Batch certification

[1.3] Biological investigational medicinal products

[1.3.1] Biological medicinal products

[1.3.1.2] Immunological products

[1.3.1.3] Cell therapy products

[1.3.1.4] Gene therapy products

[1.3.1.5] Biotechnology products

[1.3.1.8] Other biological medicinal products

Plasmid, DNA, RNA, peptides, proteins and antibody products.

Cytotoxics

[1.3.2] Batch certification

[1.3.2.2] Immunological products

[1.3.2.4] Gene therapy products

[1.3.2.5] Biotechnology products

[1.3.2.8] Other biological medicinal products

Plasmid, DNA, RNA, peptides, proteins and antibody products.

Cytotoxics

[1.4] Other products or manufacturing activity

[1.4.2] Sterilisation of active substances/excipients/finished products:

[1.4.2.1] Filtration

[1.5] Packaging

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.2] Microbiological: non-sterility

2. IMPORTATION OF MEDICINAL PRODUCTS

[2.2] Batch certification of imported medicinal products

[2.2.3] Biological medicinal products

[2.2.3.4] Gene therapy products

[2.3] Other Importation Activities

[2.3.1] Site of Physical Importation

[2.3.2] Importation of Intermediate which undergoes further processing

Restrictions or Remarks

MIA(IMP) packaging operations restricted to open label, non-randomised activities.

09/02/2026 Name and signature of the authorised person of the Competent Authority of United Kingdom
Confidential
Medicines and Healthcare products Regulatory Agency
Tel : Confidential